Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Oophorectomy and hysterectomy and cancer incidence in the Cancer Prevention Study-II Nutrition Cohort.

Gaudet MM, Gapstur SM, Sun J, Teras LR, Campbell PT, Patel AV.

Obstet Gynecol. 2014 Jun;123(6):1247-55. doi: 10.1097/AOG.0000000000000270.

PMID:
24807324
3.

The impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer--a population-based data linkage study.

Obermair A, Youlden DR, Baade PD, Janda M.

Int J Cancer. 2014 May 1;134(9):2211-22. doi: 10.1002/ijc.28537. Epub 2013 Oct 31.

4.

Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.

Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH.

Obstet Gynecol. 2006 Sep;108(3 Pt 1):515-20.

PMID:
16946209
5.

Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.

Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH.

N Engl J Med. 2006 Jan 19;354(3):261-9.

6.

Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses' Health Studies.

Rice MS, Hankinson SE, Tworoger SS.

Fertil Steril. 2014 Jul;102(1):192-198.e3. doi: 10.1016/j.fertnstert.2014.03.041. Epub 2014 May 10.

7.

Type II diabetes mellitus and the incidence of epithelial ovarian cancer in the cancer prevention study-II nutrition cohort.

Gapstur SM, Patel AV, Diver WR, Hildebrand JS, Gaudet MM, Jacobs EJ, Campbell PT.

Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2000-5. doi: 10.1158/1055-9965.EPI-12-0867. Epub 2012 Aug 31.

8.

Hysterectomy, oophorectomy, and subsequent ovarian cancer risk.

Parazzini F, Negri E, La Vecchia C, Luchini L, Mezzopane R.

Obstet Gynecol. 1993 Mar;81(3):363-6.

PMID:
8437787
9.

Ovarian cancer rates after hysterectomy with and without salpingo-oophorectomy.

Chan JK, Urban R, Capra AM, Jacoby V, Osann K, Whittemore A, Habel LA.

Obstet Gynecol. 2014 Jan;123(1):65-72. doi: 10.1097/AOG.0000000000000061.

10.

Bilateral oophorectomy and risk of cancer in African American women.

Boggs DA, Palmer JR, Rosenberg L.

Cancer Causes Control. 2014 Apr;25(4):507-13. doi: 10.1007/s10552-014-0353-y. Epub 2014 Feb 1.

11.

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.

Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A; Italian Tamoxifen Study Group..

J Natl Cancer Inst. 2007 May 2;99(9):727-37.

PMID:
17470740
12.

Determinants of the decision to perform prophylactic oophorectomy in association with a hysterectomy for a benign condition.

Plusquin C, Fastrez M, Vandromme J, Rozenberg S.

Maturitas. 2012 Oct;73(2):164-6. doi: 10.1016/j.maturitas.2012.06.014. Epub 2012 Sep 7.

PMID:
22964073
13.

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K.

N Engl J Med. 2002 May 23;346(21):1609-15. Epub 2002 May 20.

14.

National trends of adnexal surgeries at the time of hysterectomy for benign indication, United States, 1998-2011.

Mikhail E, Salemi JL, Mogos MF, Hart S, Salihu HM, Imudia AN.

Am J Obstet Gynecol. 2015 Nov;213(5):713.e1-13. doi: 10.1016/j.ajog.2015.04.031. Epub 2015 Apr 30.

PMID:
25935772
15.

The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries.

Ayhan A, Guvenal T, Salman MC, Ozyuncu O, Sakinci M, Basaran M.

Gynecol Oncol. 2005 Aug;98(2):235-41.

PMID:
15982725
16.

Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.

Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE.

Obstet Gynecol. 2009 May;113(5):1027-37. doi: 10.1097/AOG.0b013e3181a11c64.

17.

Ovarian cancer risk after salpingectomy: a nationwide population-based study.

Falconer H, Yin L, Grönberg H, Altman D.

J Natl Cancer Inst. 2015 Jan 27;107(2). pii: dju410. doi: 10.1093/jnci/dju410. Print 2015 Feb.

PMID:
25628372
18.

Hysterectomy, tubal sterilization, and the risk of breast cancer.

Irwin KL, Lee NC, Peterson HB, Rubin GL, Wingo PA, Mandel MG.

Am J Epidemiol. 1988 Jun;127(6):1192-201.

PMID:
3369418
19.

Do breast cancer survivors benefit from prophylactic removal of uterus and ovaries? A population-based data linkage replication study.

Obermair A, Youlden D, Baade P, Janda M.

Asia Pac J Clin Oncol. 2017 Feb;13(1):68-78. doi: 10.1111/ajco.12508. Epub 2016 May 27.

PMID:
27230709
20.

Long-term cancer risk after hysterectomy on benign indications: Population-based cohort study.

Altman D, Yin L, Falconer H.

Int J Cancer. 2016 Jun 1;138(11):2631-8. doi: 10.1002/ijc.30011. Epub 2016 Feb 5.

PMID:
26800386

Supplemental Content

Support Center